Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.
Argos Therapeutics Presents Data Showing the Impact of HIV Antigen Sequence Divergence on Durable Viral Control Following Treatment With Autologous Immune Therapy
Argos Therapeutics to Present at Two Upcoming Healthcare Conferences
Argos Therapeutics to Host Post-American Society of Clinical Oncology (ASCO) Conference Call and Webcast, Monday, June 9, 2014